These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 28230638)

  • 21. Total recall of radiotherapy with mTOR inhibitors: a novel and potentially frequent side-effect?
    Bourgier C; Massard C; Moldovan C; Soria JC; Deutsch E
    Ann Oncol; 2011 Feb; 22(2):485-6. PubMed ID: 21278224
    [No Abstract]   [Full Text] [Related]  

  • 22. High Incidence of Ovarian Cysts in Women Receiving mTOR Inhibitors After Renal Transplantation.
    Bachmann F; Glander P; Budde K; Bachmann C
    J Womens Health (Larchmt); 2018 Mar; 27(3):394-398. PubMed ID: 29087803
    [TBL] [Abstract][Full Text] [Related]  

  • 23. mTOR, glycotoxins and the parallel universe.
    Green AS
    Aging (Albany NY); 2018 Dec; 10(12):3654-3656. PubMed ID: 30540565
    [No Abstract]   [Full Text] [Related]  

  • 24. [Extra-renal adverse effects of mTOR inhibitors: know them to optimize their use in renal transplantation].
    Caletti C; Granata S; Tomei P; Lupo A; Zaza G
    G Ital Nefrol; 2014; 31(4):. PubMed ID: 25098457
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus.
    Sánchez-Fructuoso AI; Ruiz JC; Pérez-Flores I; Gómez Alamillo C; Calvo Romero N; Arias M
    Transplant Proc; 2010 Oct; 42(8):3050-2. PubMed ID: 20970607
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
    MacKeigan JP; Krueger DA
    Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Everolimus-induced mTOR inhibition selectively depletes macrophages in atherosclerotic plaques by autophagy.
    Martinet W; Verheye S; De Meyer GR
    Autophagy; 2007; 3(3):241-4. PubMed ID: 17224626
    [TBL] [Abstract][Full Text] [Related]  

  • 28. mTOR Inhibition and Clinical Transplantation: Liver.
    Nashan B
    Transplantation; 2018 Feb; 102(2S Suppl 1):S19-S26. PubMed ID: 28230639
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapy of sclerodermatous chronic graft-versus-host disease with mammalian target of rapamycin inhibitors.
    Jedlickova Z; Burlakova I; Bug G; Baurmann H; Schwerdtfeger R; Schleuning M
    Biol Blood Marrow Transplant; 2011 May; 17(5):657-63. PubMed ID: 20696263
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Everolimus depletes plaque macrophages, abolishes intraplaque neovascularization and improves survival in mice with advanced atherosclerosis.
    Kurdi A; Roth L; Van der Veken B; Van Dam D; De Deyn PP; De Doncker M; Neels H; De Meyer GRY; Martinet W
    Vascul Pharmacol; 2019 Feb; 113():70-76. PubMed ID: 30590134
    [TBL] [Abstract][Full Text] [Related]  

  • 31. mTOR Inhibition and Cardiovascular Diseases: Cardiac Hypertrophy.
    Paoletti E
    Transplantation; 2018 Feb; 102(2S Suppl 1):S41-S43. PubMed ID: 28230637
    [TBL] [Abstract][Full Text] [Related]  

  • 32. mTOR kinase inhibitors as a treatment strategy in hematological malignancies.
    Grzybowska-Izydorczyk O; Smolewski P
    Future Med Chem; 2012 Mar; 4(4):487-504. PubMed ID: 22416776
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: pharmacokinetic considerations and clinical implications.
    Danesi R; Boni JP; Ravaud A
    Cancer Treat Rev; 2013 Nov; 39(7):784-92. PubMed ID: 23375248
    [TBL] [Abstract][Full Text] [Related]  

  • 34. mTOR inhibitors response and mTOR pathway in pancreatic neuroendocrine tumors.
    Falletta S; Partelli S; Rubini C; Nann D; Doria A; Marinoni I; Polenta V; Di Pasquale C; Degli Uberti E; Perren A; Falconi M; Zatelli MC
    Endocr Relat Cancer; 2016 Nov; 23(11):883-891. PubMed ID: 27697900
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of everolimus on pre-existing atherosclerosis in LDL-receptor deficient mice.
    Beutner F; Brendel D; Teupser D; Sass K; Baber R; Mueller M; Ceglarek U; Thiery J
    Atherosclerosis; 2012 Jun; 222(2):337-43. PubMed ID: 22446027
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sirolimus and mTOR Inhibitors: A Review of Side Effects and Specific Management in Solid Organ Transplantation.
    Nguyen LS; Vautier M; Allenbach Y; Zahr N; Benveniste O; Funck-Brentano C; Salem JE
    Drug Saf; 2019 Jul; 42(7):813-825. PubMed ID: 30868436
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications.
    Rathkopf DE; Larson SM; Anand A; Morris MJ; Slovin SF; Shaffer DR; Heller G; Carver B; Rosen N; Scher HI
    Cancer; 2015 Nov; 121(21):3853-61. PubMed ID: 26178426
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Everolimus for the treatment of advanced renal cell carcinoma.
    Amato R
    Expert Opin Pharmacother; 2011 May; 12(7):1143-55. PubMed ID: 21470068
    [TBL] [Abstract][Full Text] [Related]  

  • 39. mTOR inhibitors in pancreas transplant: adverse effects and drug-drug interactions.
    Fernandes-Silva G; Ivani de Paula M; Rangel ÉB
    Expert Opin Drug Metab Toxicol; 2017 Apr; 13(4):367-385. PubMed ID: 27659512
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma.
    Bendtsen MAF; Grimm D; Bauer J; Wehland M; Wise P; Magnusson NE; Infanger M; Krüger M
    Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28796163
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.